Helixor M (Mistletoe Extract)
Injectable Viscum album extract from apple tree for integrative oncology support
Quick Facts about Helixor M
Key Takeaways about Helixor M
- Complementary, not alternative: Helixor M is intended to be used alongside conventional cancer treatments, never as a replacement for surgery, chemotherapy, or radiation therapy
- Immune modulation: The active mistletoe lectins and viscotoxins stimulate natural killer cells, cytokine production, and dendritic cell activation to support immune function
- Medical supervision required: Treatment must be initiated and monitored by a physician, especially during the initial dose-escalation phase when reactions are most likely
- Local reactions are expected: Redness, swelling, and warmth at the injection site are common and generally considered signs of desired immune activation
- Quality of life benefit: Clinical studies suggest improvements in fatigue, appetite, sleep quality, and overall well-being during cancer treatment
What Is Helixor M and What Is It Used For?
Helixor M is an injectable extract of European mistletoe (Viscum album) harvested from apple trees. It is used as a complementary therapy in cancer care to support immune function, reduce treatment-related side effects, and improve quality of life. It contains biologically active mistletoe lectins and viscotoxins that modulate immune responses.
Helixor M belongs to a group of medicinal products known as mistletoe preparations, which have been used in integrative oncology for over a century, particularly in Central European medicine. The extract is specifically derived from European mistletoe (Viscum album L.) growing on apple trees (Malus domestica), which gives it a characteristic biochemical profile distinct from mistletoe harvested from other host trees.
The preparation contains several biologically active compounds, the most important of which are mistletoe lectins (ML-I, ML-II, ML-III) and viscotoxins. These compounds have been extensively studied for their immunomodulatory and cytotoxic properties. Mistletoe lectins are ribosome-inactivating proteins that can bind to cell surface receptors and trigger a cascade of immune responses, including the activation of natural killer cells, the stimulation of cytokine production (particularly interleukin-1, interleukin-6, and tumor necrosis factor-alpha), and the promotion of dendritic cell maturation.
In clinical practice, Helixor M is primarily indicated as an adjunctive therapy in the treatment of malignant tumors. It is used alongside standard oncological treatments such as surgery, chemotherapy, radiation therapy, and targeted therapies. The therapeutic goals of mistletoe therapy include supporting immune function during and after cancer treatment, reducing the side effects of chemotherapy and radiation (such as fatigue, nausea, and immune suppression), and improving overall quality of life, including appetite, sleep, and emotional well-being.
It is important to emphasize that Helixor M is a complementary therapy — it is meant to complement, not replace, standard evidence-based cancer treatments. The European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) acknowledge mistletoe therapy as one of several integrative approaches that some patients may consider, while emphasizing the importance of discussing any complementary therapies with the treating oncology team.
Helixor is available in three variants based on the host tree: Helixor M (apple tree / Malus domestica), Helixor A (fir tree / Abies alba), and Helixor P (pine tree / Pinus sylvestris). Each variant has a slightly different lectin and viscotoxin composition, and the prescribing physician may select a specific variant based on the type and location of the tumor.
What Should You Know Before Taking Helixor M?
Helixor M is contraindicated in patients with known hypersensitivity to mistletoe preparations, active tuberculosis, chronic granulomatous diseases, and hyperthyroidism (unless medically managed). Special caution is required in patients with autoimmune conditions, as the immunostimulatory effects could potentially exacerbate disease activity.
Contraindications
You should not use Helixor M if any of the following conditions apply to you:
- Known allergy (hypersensitivity) to mistletoe preparations or any of the excipients in the formulation
- Active tuberculosis — the immunostimulatory effect of mistletoe extracts may worsen active tuberculous infections
- Chronic granulomatous diseases such as sarcoidosis, as immune activation may exacerbate granuloma formation
- Untreated or uncontrolled hyperthyroidism (overactive thyroid gland) — mistletoe extracts may further stimulate thyroid function
- High fever (above 38.5°C / 101.3°F) from any cause, as the immune-activating properties of the extract may intensify febrile responses
Warnings and Precautions
Before starting treatment with Helixor M, discuss the following with your prescribing physician:
- Autoimmune conditions: If you have an autoimmune disease (such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, or inflammatory bowel disease), mistletoe therapy should be used with extreme caution, as the immunostimulatory effects could potentially trigger disease flares. Your physician will carefully weigh the benefits against the risks.
- Organ transplant recipients: Patients who have received organ transplants and are on immunosuppressive medications should generally avoid mistletoe therapy, as immune stimulation may increase the risk of graft rejection.
- Hematological malignancies: In certain types of blood cancers (leukemias and lymphomas), mistletoe therapy requires careful consideration, as stimulating immune cell proliferation could theoretically affect disease dynamics. The treating oncologist should be closely involved in the decision.
- Concurrent immunotherapy: If you are receiving immune checkpoint inhibitors or other immunotherapeutic agents, the additive immunostimulatory effects of mistletoe therapy should be discussed with your oncology team.
- Allergic tendency: Patients with a history of severe allergic reactions (anaphylaxis) should begin mistletoe therapy under close medical observation, as allergic reactions to the extract have been reported, although they are rare.
Pregnancy and Breastfeeding
There is insufficient clinical data on the use of Helixor M during pregnancy and breastfeeding. As a precautionary measure, mistletoe therapy is generally not recommended during pregnancy, particularly during the first trimester, due to the potential immunostimulatory effects on the developing fetus and the lack of controlled human studies in pregnant women.
If you are pregnant, planning a pregnancy, or breastfeeding, you should discuss the risks and benefits with your healthcare provider before starting or continuing treatment. Animal studies have not demonstrated teratogenic effects, but the absence of well-controlled human studies means that a definitive safety profile during pregnancy has not been established.
During breastfeeding, it is unknown whether active components of Helixor M are excreted in breast milk. The treating physician should assess whether the benefits of continued therapy outweigh the theoretical risks to the nursing infant.
How Does Helixor M Interact with Other Drugs?
Helixor M has a relatively favorable interaction profile compared to many pharmaceutical agents. However, its immunomodulatory mechanism of action means that significant interactions may occur with immunosuppressive drugs, immune checkpoint inhibitors, and certain other medications that affect the immune system.
Because Helixor M exerts its effects primarily through immune system modulation rather than through hepatic metabolism (cytochrome P450 enzymes), the risk of pharmacokinetic drug interactions is generally considered low. However, pharmacodynamic interactions — where two drugs affect the same physiological system — are clinically relevant. The following interactions deserve attention:
Major Interactions
| Drug / Drug Class | Interaction Type | Clinical Significance |
|---|---|---|
| Immunosuppressants (cyclosporine, tacrolimus, mycophenolate) | Pharmacodynamic antagonism | Mistletoe stimulates the immune system while immunosuppressants aim to suppress it. Concomitant use may reduce the efficacy of either treatment. Generally contraindicated in transplant patients. |
| Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab) | Additive immunostimulation | Both agents stimulate immune function. Concurrent use may increase the risk of immune-related adverse events (irAEs) such as colitis, hepatitis, or pneumonitis. Close monitoring required. |
| High-dose corticosteroids (prednisone, dexamethasone >10 mg/day) | Pharmacodynamic antagonism | High-dose corticosteroids suppress the immune system and may diminish the immunomodulatory effects of Helixor M. Short courses for chemotherapy premedication are generally acceptable. |
Minor Interactions
| Drug / Drug Class | Interaction Type | Clinical Significance |
|---|---|---|
| Antipyretics (paracetamol, ibuprofen) | May mask desired fever response | Mild fever following injection is an expected immune response. Routine antipyretic use may blunt this intended therapeutic effect, though short-term use for discomfort is generally acceptable. |
| Standard chemotherapy agents (5-FU, cisplatin, doxorubicin) | Potential additive effect | Clinical studies have not shown significant negative interactions. Some evidence suggests mistletoe therapy may reduce chemotherapy-induced leukopenia and improve tolerance. Timing of administration may be important. |
| Anticoagulants (warfarin, heparin) | Theoretical | No clinically significant interactions have been demonstrated in published literature. Standard monitoring of coagulation parameters is advised. |
| Thyroid medications (levothyroxine) | Theoretical potentiation | Mistletoe extracts may affect thyroid function. Thyroid function tests should be monitored in patients on thyroid replacement therapy, particularly during initiation of mistletoe therapy. |
Before starting Helixor M, provide your treating physician with a complete list of all medications you are taking, including prescription drugs, over-the-counter medications, dietary supplements, and herbal products. This includes any other complementary or alternative medicines you may be using.
What Is the Correct Dosage of Helixor M?
Helixor M dosing follows an individualized, gradual escalation protocol. Treatment typically begins with very low doses (0.01–0.1 mg) administered two to three times per week by subcutaneous injection, with progressive increases based on the patient's tolerability and local reaction pattern. The target maintenance dose varies by individual and is determined by the treating physician.
The dosing of Helixor M is highly individualized and follows a principle of graduated dose escalation. Unlike many pharmaceutical products with fixed dosing regimens, mistletoe therapy is titrated based on the patient's individual response, particularly the local reaction at the injection site and any systemic symptoms such as mild fever. The goal is to find an optimal maintenance dose that produces a measurable immune response without causing excessive side effects.
Adults
Standard Dose Escalation Protocol
Initiation phase (weeks 1–4): Treatment typically begins with a low dose, such as 0.01 mg, administered by subcutaneous injection two to three times per week. The dose is gradually increased in a stepwise fashion (e.g., 0.01 mg → 0.1 mg → 1 mg → higher doses as tolerated) over several weeks, guided by the local skin reaction and systemic response.
Maintenance phase: Once the optimal individual dose has been established, treatment continues at the maintenance dose, typically administered two to three times per week. The maintenance dose is the highest dose that produces a mild local reaction (redness up to 5 cm diameter at the injection site) without significant systemic side effects.
Duration of treatment: The treatment duration is determined by the treating physician based on the clinical situation. Mistletoe therapy is often continued for several months to years, including during and after conventional cancer treatment.
| Patient Group | Starting Dose | Maintenance Dose | Frequency |
|---|---|---|---|
| Adults (standard) | 0.01–0.1 mg | Individualized (typically 1–20 mg) | 2–3 times per week |
| Elderly (>65 years) | 0.01 mg (lower start recommended) | Individualized (may require lower doses) | 2–3 times per week |
| Sensitive patients | 0.001–0.01 mg | Individualized (slower escalation) | 2–3 times per week |
Children
Helixor M is not routinely recommended for children unless specifically prescribed by a specialist physician experienced in pediatric integrative oncology. There is limited clinical data on the use of mistletoe preparations in pediatric patients, and dosing must be individually determined by the treating physician if use is considered appropriate. In rare cases where pediatric use is pursued, lower starting doses and slower escalation schedules are employed.
Elderly
Elderly patients (over 65 years of age) may be more sensitive to the immunostimulatory effects of Helixor M. It is generally recommended to begin with the lowest available starting dose and to escalate more slowly than in younger adults. The treating physician should closely monitor the local reaction pattern and any systemic symptoms, adjusting the dose as needed. Renal and hepatic function should be assessed as part of the overall clinical evaluation, although Helixor M is not primarily metabolized through these organ systems.
Missed Dose
If you miss a scheduled dose of Helixor M, administer the injection as soon as you remember, provided there is sufficient time before the next scheduled dose. Do not double the dose to compensate for a missed injection. If you are unsure about timing, contact your prescribing physician or pharmacist for guidance. A single missed dose is unlikely to significantly affect the overall course of treatment, but consistent administration is important for maintaining the desired immunomodulatory effect.
Overdose
If an excessive dose of Helixor M is administered, the patient may experience intensified side effects, including pronounced local reactions (significant redness, swelling, and pain at the injection site), higher fever (potentially above 39°C / 102.2°F), chills, headache, and general malaise. In the event of a suspected overdose:
- Seek medical attention immediately
- Symptomatic treatment should be provided, including antipyretics for fever and anti-inflammatory medications for severe local reactions
- Monitor vital signs and observe the patient for several hours
- Subsequent doses should be reduced, and the dose-escalation protocol should be reassessed
Helixor M is for subcutaneous injection only. It should never be administered intravenously, intramuscularly, or directly into a tumor without specific medical guidance. Intravenous administration of mistletoe extracts can cause severe systemic reactions. Always follow the injection technique instructions provided by your healthcare team.
What Are the Side Effects of Helixor M?
The most common side effects of Helixor M are local injection site reactions (redness, swelling, warmth) and mild systemic responses such as low-grade fever and fatigue. These are generally considered signs of immune activation and typically resolve within 24–48 hours. Serious adverse reactions are uncommon but can include allergic reactions and, rarely, anaphylaxis.
Like all medicines, Helixor M can cause side effects, although not everybody gets them. The side effect profile of mistletoe preparations has been well-characterized through decades of clinical use and numerous clinical studies involving thousands of patients. In general, mistletoe therapy is considered to have a favorable safety profile when administered according to the recommended dosing guidelines.
It is important to understand that local injection site reactions are intentional — they indicate that the immune system is responding to the mistletoe extract. A mild local reaction (redness up to 5 cm in diameter) is generally considered desirable and guides dose adjustment. If the local reaction is absent, the dose may need to be increased; if it is excessive (greater than 5 cm), the dose should be reduced.
Very Common (affects more than 1 in 10 patients)
- Local injection site reactions: redness, swelling, warmth, and mild pain at the injection site
- Induration (hardening) at the injection site
- Mild itching at the injection site
Common (affects 1 in 10 to 1 in 100 patients)
- Low-grade fever (up to 38°C / 100.4°F), typically occurring 4–12 hours after injection
- Fatigue and mild malaise lasting 12–24 hours
- Mild headache
- Mild flu-like symptoms (body aches, chills)
- Regional lymph node enlargement near the injection site
Uncommon (affects 1 in 100 to 1 in 1,000 patients)
- Localized allergic skin reactions (urticaria near the injection site)
- Nausea and gastrointestinal discomfort
- Transient elevation of inflammatory markers (C-reactive protein, erythrocyte sedimentation rate)
- Muscle and joint pain
- Dizziness
Rare (affects fewer than 1 in 1,000 patients)
- Generalized allergic reaction requiring medical intervention
- Anaphylaxis (extremely rare; immediate emergency treatment required)
- Autoimmune-like phenomena (e.g., transient exacerbation of pre-existing autoimmune conditions)
- Granulomatous inflammation at the injection site (with prolonged use at the same site)
Contact your healthcare provider immediately or go to the nearest emergency room if you experience any of the following after an injection: difficulty breathing, facial or throat swelling, widespread hives or rash, rapid heartbeat, severe dizziness, or fainting. These may be signs of a serious allergic reaction that requires immediate treatment.
If you experience side effects that are bothersome or do not resolve as expected, report them to your prescribing physician. Your dose may need to be adjusted. You can also report side effects to your national pharmacovigilance authority to help monitor the safety of this medicine.
How Should You Store Helixor M?
Helixor M must be stored in a refrigerator at 2–8°C (36–46°F) and protected from light. Do not freeze. Keep the ampoules in the original carton until use. Once opened, use immediately — do not store opened ampoules for later use.
Proper storage is essential to maintain the potency and safety of Helixor M, as the biologically active proteins (mistletoe lectins and viscotoxins) are sensitive to temperature and light degradation. Follow these storage guidelines carefully:
- Temperature: Store at 2–8°C (36–46°F) in a refrigerator. Do not freeze, as freezing can denature the active proteins and render the product ineffective.
- Light protection: Keep the ampoules in the original outer carton to protect them from light. Prolonged exposure to light can degrade the mistletoe lectins.
- Transport: If you need to transport Helixor M (for example, when traveling), use a cooler bag with a cold pack. Ensure the ampoules do not come into direct contact with the cold pack to avoid accidental freezing. Brief excursions to room temperature (up to 25°C / 77°F) for a few hours are generally acceptable, but prolonged storage outside refrigerated conditions should be avoided.
- Opened ampoules: Use immediately after opening. Do not store partially used ampoules. Discard any unused solution.
- Shelf life: Do not use after the expiry date stated on the carton and ampoule label. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use.
Store Helixor M in a safe location in the refrigerator where children cannot access it. The injection solution should only be handled by the patient (after appropriate training) or a healthcare professional.
What Does Helixor M Contain?
The active substance in Helixor M is an aqueous extract of fresh European mistletoe herb (Viscum album L.) harvested from apple trees (Malus domestica). The extract contains a standardized profile of biologically active compounds including mistletoe lectins, viscotoxins, and various polysaccharides.
Understanding the composition of Helixor M helps to appreciate how it differs from other mistletoe preparations and why the host tree species matters in terms of the biochemical profile of the extract.
Active Substance
The active substance is a fresh plant extract of Viscum album L. (European mistletoe) from the host tree Malus domestica (apple tree). The extraction process preserves the native protein structure of the biologically active components, including:
- Mistletoe lectins (ML-I, ML-II, ML-III): These are ribosome-inactivating proteins with both immunomodulatory and direct cytotoxic properties. ML-I is the most extensively studied and consists of an A-chain (enzymatic activity) and a B-chain (cell-binding activity).
- Viscotoxins: Small basic proteins (approximately 46 amino acids) with membrane-lytic activity. They contribute to the local immune response at the injection site.
- Polysaccharides: Complex carbohydrates that contribute to the immunostimulatory effect by activating complement pathways and stimulating phagocytic cells.
- Flavonoids and phenolic acids: Antioxidant compounds that may provide additional cytoprotective effects.
Excipients (Inactive Ingredients)
The excipients in Helixor M serve to stabilize the active extract and provide a suitable vehicle for injection. They typically include:
- Sodium chloride: To adjust the osmolarity of the solution for comfortable injection
- Water for injections: The sterile vehicle
Helixor M does not contain preservatives, artificial colorings, or fragrances. The preparation is free from gluten and lactose. The manufacturing process follows Good Manufacturing Practice (GMP) standards to ensure consistent quality and batch-to-batch reproducibility of the lectin and viscotoxin content.
Frequently Asked Questions about Helixor M
Helixor M is an injectable mistletoe extract (Viscum album) derived from apple tree host plants (Malus domestica). It is used as an adjunctive therapy in integrative oncology to support the immune system and improve quality of life in cancer patients undergoing conventional treatment. It contains biologically active mistletoe lectins and viscotoxins that modulate immune responses, stimulating natural killer cells and cytokine production.
No. Helixor M is a complementary therapy intended to be used alongside standard cancer treatments such as surgery, chemotherapy, and radiation therapy. It should never be used as a sole treatment for cancer or as a replacement for evidence-based oncological care. Its role is to support immune function, reduce treatment-related side effects, and improve overall quality of life during cancer treatment.
Helixor M is administered by subcutaneous injection (under the skin), typically into the abdomen or thigh area. It is given two to three times per week. The initial injections should be administered under medical supervision, and patients can be trained to self-inject at home once the appropriate dose has been established and the technique has been mastered. The injection site should be rotated to prevent localized skin reactions.
The three Helixor variants differ by the host tree from which the mistletoe is harvested. Helixor M comes from apple trees (Malus domestica), Helixor A from fir trees (Abies alba), and Helixor P from pine trees (Pinus sylvestris). Each variant has a slightly different lectin and viscotoxin profile. The prescribing physician may choose a specific variant based on the patient's tumor type, treatment response, and individual tolerance.
Yes. Local injection site reactions such as redness, swelling, and mild warmth are very common and are generally considered a desirable sign that the immune system is responding to the mistletoe extract. A mild local reaction (redness up to about 5 cm in diameter) is typically used as a guide for dose adjustment. If the reaction is absent, the dose may need to be increased; if it exceeds 5 cm, the dose may need to be reduced. These reactions usually resolve within 24–48 hours.
The duration of treatment with Helixor M is individually determined by the treating physician based on the patient's clinical situation. Mistletoe therapy is often continued for several months to years, potentially including the entire period of active cancer treatment and a follow-up period thereafter. Some patients continue therapy long-term for maintenance of quality of life and immune support. Regular reassessments are conducted to determine whether continued treatment remains appropriate.
References
- Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. European Journal of Medical Research. 2007;12(3):103-119.
- Trogen B, et al. Viscum album [L.] extracts in cancer treatment: a systematic review of controlled clinical trials. Phytomedicine. 2020;77:153271. doi:10.1016/j.phymed.2020.153271
- Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. 2020;20:227. doi:10.1186/s12906-020-03013-3
- European Medicines Agency (EMA). Assessment report on Viscum album L., herba. Committee on Herbal Medicinal Products (HMPC). EMA/HMPC/246778/2009.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Survivorship. Version 1.2024. Complementary and integrative medicine section.
- Kienle GS, Grugel R, Kiene H. Safety of higher dosages of Viscum album L. in animals and humans – systematic review of immune changes and safety parameters. BMC Complementary and Alternative Medicine. 2011;11:72. doi:10.1186/1472-6882-11-72
- Ostermann T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer. 2009;9:451. doi:10.1186/1471-2407-9-451
- Horneber M, et al. Mistletoe therapy in oncology. Cochrane Database of Systematic Reviews. 2008;(2):CD003297. doi:10.1002/14651858.CD003297.pub2
- World Health Organization (WHO). WHO Monographs on Selected Medicinal Plants. Volume 4. Geneva: WHO; 2009. Viscum album.
- Büssing A. Mistletoe: The Genus Viscum. Medicinal and Aromatic Plants – Industrial Profiles. CRC Press; 2000.
Editorial Team
Medical Review
This article has been reviewed by the iMedic Medical Review Board, an independent panel of board-certified physicians specializing in clinical pharmacology, integrative oncology, and evidence-based complementary medicine.
Evidence Standards
All medical claims are supported by peer-reviewed research and follow the GRADE evidence framework. References include systematic reviews, meta-analyses, and guidelines from recognized medical organizations (EMA, NCCN, WHO).
Last reviewed: | Published: | Meet our medical team